FDA 101 Webinar
An overview of FDA’s basic functions and jurisdiction, and the regulatory framework that determines how the agency functions and accomplishes its various responsibilities, presented by Dave Banks from the Office of Health and Constituent Affairs.
- Thursday, April 18, 2013
3:00 PM – 4:00 PM
Eastern Time Zone
Registration is required.
Remember to submit comments to the FDA
The suggested topics include:
Topic 1: Disease Symptoms and Daily Impacts That Matter Most to Patients
- What are the most significant symptoms that you experience resulting from your condition? (Examples may include prolonged exhaustion, confusion, muscle pain, heat or cold intolerance.)
- What are the most negative impacts on your daily life that result from your condition and its symptoms? (Examples may include difficulty with specific activities, such as sleeping through the night.)
- How does the condition affect your daily life on the best days and worst days?
- What changes have you had to make in your life because of your condition?
Topic 2: Patients’ Perspectives on Current Approaches To Treating CFS and ME
- What treatments are you currently using to help treat your condition or its symptoms? (Examples may include FDA-approved medicines, over-the- counter products, and other therapies, including non-drug therapies such as activity limitations.)
- What specific symptoms do your treatments address?
- How has your treatment regimen changed over time and why?
- How well does your current treatment regimen treat the most significant symptoms of your disease?
- Have these treatments improved your daily life (for example, improving your ability to do specific activities)? Please explain.
- How well have these treatments worked for you as your condition has changed over time?
- What are the most significant downsides of these treatments (for example, specific side effects)?
In addition to the questions that the FDA asked, please provide comments about your lab/test abnormalities – linked to symptoms and dysfunction where possible – and indicate how those abnormalities changed as a result of treatment if known.
TO SUBMIT COMMENTS:
- Go here and submit comments now by clicking on the ‘Comment Now!” box in the upper right corner of the page.
- You can also submit written comments to Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Include the docket number, which is “FDA-2012-N-0962-0004”.
- The Docket is open until August 2, 2013.
- The FDA is encouraging patients to provide answers to the questions asked in the Federal Register. But again, don’t forget to also include information about the biological abnormalities – linked to symptoms where possible – and indicate how those abnormalities changed as a result of treatment if known.